The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Comprehensive Research Report: TRA2B (Transformer-2 Protein Homolog Beta)

1. Gene and Protein Identity

TRA2B (also known as SFRS10) encodes Transformer-2 protein homolog beta (TRA2β), a sequence-specific RNA-binding protein and splicing activator belonging to the serine/arginine-rich (SR)-like protein family (swarup2025dualroleof pages 2-4, best2014humantra2proteins pages 1-2, swarup2025dualroleof pages 1-2). The gene is located on human chromosome 3q27.2 and produces a protein (UniProt P62995) that is the mammalian homolog of the Drosophila sex-determination factor Transformer-2 (swarup2025dualroleof pages 1-2, xue2023tra2thedominant pages 1-3). In humans, the Tra2 family comprises two paralogs—TRA2A and TRA2B—which share approximately 75% overall sequence identity and have partially overlapping functions (xue2023tra2thedominant pages 5-7, xue2023tra2thedominant pages 1-3). TRA2B is typically expressed at substantially higher levels than TRA2A in most human cell types (best2014humantra2proteins pages 1-2).

The following table provides a structured summary of TRA2B's key properties:

Table: This table summarizes the validated structural features, localization, and core functional properties of human TRA2B/ SFRS10. It is useful as a quick-reference overview linking domain architecture and RNA-binding specificity to TRA2B’s role as an autoregulated splicing activator.

2. Protein Structure and Domain Architecture

TRA2β possesses a characteristic modular domain organization consisting of a single central RNA Recognition Motif (RRM) flanked by two arginine/serine-rich (RS) domains: RS1 at the N-terminus and RS2 at the C-terminus (swarup2025dualroleof pages 2-4, best2014humantra2proteins pages 1-2, xue2023tra2thedominant pages 1-3). The RRM domain is the primary determinant of RNA-binding specificity and directly interacts with target pre-mRNA sequences to facilitate spliceosome assembly (swarup2025dualroleof pages 2-4, swarup2025dualroleof pages 1-2). The RRM is highly conserved, sharing approximately 85% sequence identity with TRA2A and 54% identity with Drosophila TRA2 (swarup2025dualroleof pages 1-2). The RS domains mediate both protein–protein and protein–RNA interactions that are critical for splice site selection and exon inclusion; they also facilitate RNA–RNA base pairing and interaction with other RS-domain-containing proteins in the spliceosome (swarup2025dualroleof pages 2-4, best2014humantra2proteins pages 1-2).

The TRA2B gene produces multiple splice isoforms. The full-length isoform TRA2β-L contains all functional domains (RS1–RRM–RS2), while the truncated isoform TRA2β-S lacks exon 2 and consequently the RS1 domain, retaining only the RRM and RS2 (swarup2025dualroleof pages 2-4). Importantly, the N-terminal RS1 domain is essential for the splicing activator function of TRA2β: isoforms lacking this domain not only lose activator activity but can potently repress the same target exons that are activated by full-length TRA2β protein (grellscheid2011identificationofevolutionarily pages 1-2, grellscheid2011identificationofevolutionarily pages 5-6). This domain-dependent functional switch between activation and repression represents a key regulatory mechanism.

3. RNA Binding Specificity and Mechanism

TRA2β preferentially recognizes and binds AGAA-rich sequences, with the extended consensus motif AGAAGA representing the most frequently identified binding site in transcriptome-wide CLIP studies (~20% of CLIP tags) (grellscheid2011identificationofevolutionarily pages 4-5, swarup2025dualroleof pages 2-4). The GAA trinucleotide core is essential for efficient RNA-protein interaction: when only a single GAA triplet is present, 89% of binding events contain a downstream G residue (GAAG) (grellscheid2011identificationofevolutionarily pages 4-5). Modifications to the AGAA motif—such as replacing the first A with C, G, or T—reduce binding affinity approximately 2-fold (xue2023tra2thedominant pages 5-7). In addition to AGAA-rich sequences, CAA-rich single-stranded sequences have also been identified as TRA2β binding targets (best2014humantra2proteins pages 1-2, grellscheid2011identificationofevolutionarily pages 4-5). TRA2β can adopt alternative RNA-binding modes, including binding to stem-loop RNA structures (xue2023tra2thedominant pages 5-7).

HITS-CLIP analysis in mouse testis demonstrated that approximately 69% of Tra2β binding sites map to protein-coding genes, with 29% located specifically within exons (grellscheid2011identificationofevolutionarily pages 4-5). TRA2β binds to exonic splicing enhancers (ESEs) positioned close to regulatory splice sites, strengthening spliceosome assembly and promoting exon inclusion (xue2023tra2thedominant pages 3-4). Efficient splicing activation of target exons frequently requires multiple cooperative TRA2β binding sites, explaining why regulated exons tend to be longer than average and contain a high density of binding motifs (grellscheid2011identificationofevolutionarily pages 5-6, grellscheid2011identificationofevolutionarily pages 1-2). Electrophoretic mobility shift assays (EMSA) have demonstrated that very low concentrations of Tra2β protein (50 ng) can form large protein-RNA complexes, indicative of high-affinity binding (grellscheid2011identificationofevolutionarily pages 5-6).

4. Primary Function: Splicing Activation

The primary molecular function of TRA2β is as a sequence-specific splicing activator that promotes exon inclusion in pre-mRNAs (xue2023tra2thedominant pages 3-4, grellscheid2011identificationofevolutionarily pages 1-2). TRA2β activates cassette exons—the most common form of alternative splicing in human and mouse cells—and can activate both weak 3' and 5' splice sites (xue2023tra2thedominant pages 3-4). It achieves this by binding to ESE sequences and recruiting spliceosomal components to promote productive splice site recognition (xue2023tra2thedominant pages 3-4, swarup2025dualroleof pages 2-4).

Beyond direct RNA-binding-dependent activation, TRA2β can also function as a splicing co-activator independent of its own RRM-mediated RNA binding (grellscheid2011identificationofevolutionarily pages 1-2). This dual mechanism—direct activation via RNA binding and indirect co-activation—expands the repertoire of exons that TRA2β can regulate. Importantly, the N-terminal RS1 domain, which is conserved between flies and humans, is indispensable for splicing activation; versions of TRA2β lacking RS1 function as potent repressors rather than activators of the same target exons (grellscheid2011identificationofevolutionarily pages 1-2, grellscheid2011identificationofevolutionarily pages 5-6).

5. Subcellular Localization

TRA2β is predominantly a nuclear protein that carries out its splicing regulatory functions in the nucleus, consistent with its role in pre-mRNA processing (grellscheid2011identificationofevolutionarily pages 4-5). Immunohistochemistry of mouse testis sections using affinity-purified antibodies revealed strong nuclear staining in spermatocytes, round spermatids, and elongating spermatids (grellscheid2011identificationofevolutionarily pages 4-5). Immunohistochemistry across 79 standard tissue cell types revealed strong nucleolar staining, with some cytoplasmic and membrane localization also observed (xue2023tra2thedominant pages 5-7). The nuclear localization is consistent with the protein's function at sites of pre-mRNA splicing, where it interacts with the spliceosome and other SR-domain-containing proteins.

6. Autoregulation via Poison Exon and Paralog Compensation

A critical feature of TRA2β biology is its autoregulatory negative feedback mechanism. TRA2β regulates its own expression by promoting inclusion of an ultra-conserved poison exon (PE) located between exons 1 and 2 of its own TRA2B pre-mRNA (swarup2025dualroleof pages 2-4, dalgliesh2025anultraconservedpoison pages 1-2). When TRA2β protein levels rise, the protein binds to its own PE and activates its inclusion, introducing a premature stop codon that targets the resulting transcript for nonsense-mediated decay (NMD) (dalgliesh2025anultraconservedpoison pages 1-2, dalgliesh2025ultra‐conservedpoisonexons pages 2-4). This limits further protein accumulation and prevents toxic overexpression. The PE is remarkably conserved: it is 100% identical in sequence between humans, mice, and rats, and 96% conserved across approximately 300 million years of vertebrate evolution, underscoring its functional importance (swarup2025dualroleof pages 2-4).

In addition to self-regulation, TRA2β cross-regulates its paralog TRA2A via a poison exon mechanism: TRA2β activates inclusion of a poison exon in TRA2A mRNA, thereby repressing TRA2A protein expression (best2014humantra2proteins pages 1-2). This paralog compensation system ensures that simultaneous depletion of both proteins—but not individual depletion—produces substantial shifts in splicing of endogenous target exons, as the remaining paralog can compensate for loss of the other (best2014humantra2proteins pages 1-2).

7. Key Splicing Targets and Biological Pathways

TRA2β regulates the alternative splicing of a diverse set of target transcripts across multiple biological pathways. The following table summarizes the major validated targets:

Table: This table summarizes experimentally supported TRA2B-regulated splicing targets, the direction of their splicing regulation, and the biological and disease contexts in which those targets are relevant. It provides a compact map of TRA2B’s best-supported functional outputs across DNA damage response, metabolism, neurobiology, fertility, and cancer.

7.1 DNA Damage Response: CHEK1

A landmark study published in Nature Communications demonstrated that TRA2α and TRA2β jointly control splicing of CHEK1 exon 3, which is required for production of full-length CHK1 protein, a key DNA damage checkpoint kinase (best2014humantra2proteins pages 1-2). Dual depletion of both Tra2 proteins reduces full-length CHK1 protein levels, causes accumulation of the DNA damage marker γH2AX, and decreases cell viability (swarup2025dualroleof pages 7-9, best2014humantra2proteins pages 1-2). Target exons regulated by Tra2 proteins are enriched in genes associated with chromosome biology (best2014humantra2proteins pages 1-2).

7.2 Hepatic Lipogenesis and Metabolic Regulation: LPIN1

In a highly cited study in Cell Metabolism, Pihlajamäki et al. (2011) demonstrated that expression of SFRS10/TRA2B is reduced in liver and skeletal muscle of obese humans, and that this reduction contributes to enhanced lipogenesis (pihlajamaki2011expressionofthe pages 1-2). TRA2β directly regulates LPIN1 splicing by binding to GGAA motifs in the alternatively spliced exon 6: when TRA2β levels are high, it promotes exon 6 skipping and favors the LPIN1a isoform, whereas reduced TRA2β levels increase LPIN1b (the lipogenic isoform) (pihlajamaki2011expressionofthe pages 4-5). In Sfrs10 heterozygous mice with approximately 30% reduced mRNA levels, there was increased hepatic lipogenic gene expression (Srebp1c, Fasn, Scd1, Dgat2, Agpat2), elevated VLDL secretion, and hypertriglyceridemia (pihlajamaki2011expressionofthe pages 1-2, pihlajamaki2011expressionofthe pages 4-5, pihlajamaki2011expressionofthe pages 3-4). Critically, LPIN1b-specific siRNA abolished the lipogenic effects of reduced SFRS10, establishing LPIN1 splicing as a direct mediator (pihlajamaki2011expressionofthe pages 1-2).

7.3 Neurodevelopment and Neuronal Survival

TRA2β is essential for brain development. Neuronal-specific Tra2b knockout mice (Sfrs10fl/fl; Nestin-Cretg/+) die immediately after birth and exhibit severe cortical malformations caused by massive apoptosis in ventricular layers of the cortex (grellscheid2011identificationofevolutionarily pages 1-2). In vivo exon array analysis identified Tubulinδ1 and Shugoshin-like2 as neuronal Tra2b splicing targets, and loss of Tra2b led to upregulation of the cyclin-dependent kinase inhibitor p21, functionally linked to neuronal precursor cell death (grellscheid2011identificationofevolutionarily pages 1-2). Clustered variants in the 5' coding region of TRA2B have been identified as causing a distinctive neurodevelopmental syndrome in humans, further establishing TRA2β's essential role in neurogenesis (swarup2025dualroleof pages 12-14, swarup2025dualroleof pages 14-15). OpenTargets data associate TRA2B with syndromic complex neurodevelopmental disorder, schizophrenia, and blindness among other conditions (OpenTargets Search: -TRA2B).

7.4 Spinal Muscular Atrophy: SMN2 Exon 7

TRA2β promotes inclusion of SMN2 exon 7 in vitro, which is the critical splicing event determining the severity of spinal muscular atrophy (SMA) (swarup2025dualroleof pages 12-14, swarup2025dualroleof pages 7-9). However, the in vivo effect appears limited unless TRA2β is highly overexpressed, suggesting that TRA2β contributes to but is not the sole determinant of SMN2 exon 7 inclusion in the SMA context (swarup2025dualroleof pages 7-9).

7.5 Alzheimer's Disease: RAGE Splicing

TRA2β regulates splicing of the receptor for advanced glycation end-products (RAGE/AGER), promoting production of the soluble decoy receptor esRAGE at the expense of the membrane-bound mRAGE isoform (swarup2025dualroleof pages 7-9). This activity functionally opposes hnRNP A1, which promotes mRAGE splicing, positioning TRA2β as a modulator of the AGE/RAGE inflammatory signaling axis in neurodegeneration (swarup2025dualroleof pages 7-9).

7.6 Male Fertility and Meiosis: Poison Exon Function

A 2025 study in The EMBO Journal established that the ultra-conserved TRA2B poison exon is essential for male fertility and meiotic cell division (dalgliesh2025anultraconservedpoison pages 1-2). Genetic deletion of the Tra2b PE in mice causes azoospermia due to catastrophic cell death during meiotic prophase (dalgliesh2025anultraconservedpoison pages 1-2, dalgliesh2025ultra‐conservedpoisonexons pages 2-4). Without the PE to limit TRA2β concentration, protein levels become excessive in pachytene cells, driving aberrant hyper-responsive splice patterns and activating cryptic splice sites in meiosis-critical genes such as Ptbp2, generating unstable mRNAs that compromise cell function (dalgliesh2025ultra‐conservedpoisonexons pages 2-4). Notably, earlier mitotically active germ cells are spared despite still requiring Tra2b gene function, indicating that the PE-mediated concentration control is specifically critical during the meiotic transition (dalgliesh2025anultraconservedpoison pages 1-2). Deletion of the TRA2B PE also has cell-type-specific effects beyond the germline: in activated T cells, it enhances proliferation but reduces long-term survival (dalgliesh2025ultra‐conservedpoisonexons pages 6-7).

8. Role in Cancer

TRA2β functions as a proto-oncogene when upregulated in multiple cancer types. The TRA2B gene is amplified in tumors of the lung, ovary, cervix, stomach, head, and neck (swarup2025dualroleof pages 9-10, xue2023tra2thedominant pages 5-7). Both TRA2B mRNA and TRA2β protein are upregulated in breast, cervical, ovarian, and colon cancers, and overexpression is associated with poor prognosis (swarup2025dualroleof pages 9-10, swarup2025dualroleof pages 12-14). TRA2B transcription is regulated by the proto-oncogene ETS-1, which may drive its elevated expression in cancer cells (xue2023tra2thedominant pages 7-8).

Key oncogenic splicing events regulated by TRA2β include: promoting CD44 exon v4/v5 inclusion to enhance cancer cell invasiveness (xue2023tra2thedominant pages 5-7); activating the PI3K/AKT pathway in laryngeal carcinoma (xue2023tra2thedominant pages 7-8); and regulating genes involved in cell cycle progression, cell adhesion, and angiogenesis in ovarian cancer (swarup2025dualroleof pages 9-10). In prostate cancer, a landmark study published in the Journal of Clinical Investigation demonstrated that TRA2B enhances synthesis of the androgen receptor splice variant AR-V7, a constitutively active receptor variant that drives treatment resistance in castration-resistant prostate cancer (CRPC) (brittain2026splicingfactortra2b pages 9-10, brittain2026splicingfactortra2b pages 1-2). The AR cryptic exon CE3, which encodes AR-V7, contains an elevated frequency of AGAA binding motifs (2.4-fold above average), and depletion of TRA2A/B reduces AR-V7 protein and suppresses growth of AR-V7-positive prostate cancer cells by 50–70% (brittain2026splicingfactortra2b pages 9-10). Antisense oligonucleotides targeting TRA2β (ASO-1570) have shown anti-cancer effects in glioblastoma, triple-negative breast cancer, and colorectal cancer models (swarup2025dualroleof pages 12-14).

9. Summary of Signaling and Biochemical Context

TRA2β operates at the nexus of post-transcriptional gene regulation, controlling the output of biologically critical splicing decisions across multiple cellular contexts. It does not function as an enzyme catalyzing a chemical reaction; rather, it is a sequence-specific RNA-binding adapter protein that facilitates spliceosome assembly at target exons by recognizing AGAA-rich exonic splicing enhancers through its RRM domain and recruiting spliceosomal components via its RS domains (swarup2025dualroleof pages 2-4, xue2023tra2thedominant pages 3-4). Its concentration-dependent activity, controlled by an ultra-conserved poison exon autoregulatory mechanism and paralog compensation with TRA2A, ensures precise splicing regulation across developmental stages and cell types (best2014humantra2proteins pages 1-2, dalgliesh2025anultraconservedpoison pages 1-2, dalgliesh2025ultra‐conservedpoisonexons pages 2-4). Dysregulation of this tightly controlled system—whether through gene amplification in cancer, reduced expression in obesity, or coding-region mutations in neurodevelopmental disorders—has profound pathological consequences that illuminate TRA2β's central role in splicing homeostasis.

References

1. (swarup2025dualroleof pages 2-4): Evan Swarup and Hongyu Qiu. Dual role of transformer 2 beta as both a developmental necessity and a disease modulator. International Journal of Molecular Sciences, 26:8805, Sep 2025. URL: https://doi.org/10.3390/ijms26188805, doi:10.3390/ijms26188805. This article has 0 citations.

2. (best2014humantra2proteins pages 1-2): Andrew Best, Katherine James, Caroline Dalgliesh, Elaine Hong, Mahsa Kheirolahi-Kouhestani, Tomaz Curk, Yaobo Xu, Marina Danilenko, Rafiq Hussain, Bernard Keavney, Anil Wipat, Roscoe Klinck, Ian G. Cowell, Ka Cheong Lee, Caroline A. Austin, Julian P. Venables, Benoit Chabot, Mauro Santibanez Koref, Alison Tyson-Capper, and David J. Elliott. Human tra2 proteins jointly control a chek1 splicing switch among alternative and constitutive target exons. Nature Communications, Sep 2014. URL: https://doi.org/10.1038/ncomms5760, doi:10.1038/ncomms5760. This article has 82 citations and is from a highest quality peer-reviewed journal.

3. (swarup2025dualroleof pages 1-2): Evan Swarup and Hongyu Qiu. Dual role of transformer 2 beta as both a developmental necessity and a disease modulator. International Journal of Molecular Sciences, 26:8805, Sep 2025. URL: https://doi.org/10.3390/ijms26188805, doi:10.3390/ijms26188805. This article has 0 citations.

4. (xue2023tra2thedominant pages 1-3): Jiancheng Xue, Tie Ma, and Xiaowen Zhang. Tra2: the dominant power of alternative splicing in tumors. Heliyon, 9:e15516, Apr 2023. URL: https://doi.org/10.1016/j.heliyon.2023.e15516, doi:10.1016/j.heliyon.2023.e15516. This article has 19 citations.

5. (xue2023tra2thedominant pages 5-7): Jiancheng Xue, Tie Ma, and Xiaowen Zhang. Tra2: the dominant power of alternative splicing in tumors. Heliyon, 9:e15516, Apr 2023. URL: https://doi.org/10.1016/j.heliyon.2023.e15516, doi:10.1016/j.heliyon.2023.e15516. This article has 19 citations.

6. (OpenTargets Search: -TRA2B): Open Targets Query (-TRA2B, 5 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

7. (grellscheid2011identificationofevolutionarily pages 4-5): Sushma Grellscheid, Caroline Dalgliesh, Markus Storbeck, Andrew Best, Yilei Liu, Miriam Jakubik, Ylva Mende, Ingrid Ehrmann, Tomaz Curk, Kristina Rossbach, Cyril F. Bourgeois, James Stévenin, David Grellscheid, Michael S. Jackson, Brunhilde Wirth, and David J. Elliott. Identification of evolutionarily conserved exons as regulated targets for the splicing activator tra2β in development. PLoS Genetics, 7:e1002390, Dec 2011. URL: https://doi.org/10.1371/journal.pgen.1002390, doi:10.1371/journal.pgen.1002390. This article has 103 citations and is from a domain leading peer-reviewed journal.

8. (xue2023tra2thedominant pages 3-4): Jiancheng Xue, Tie Ma, and Xiaowen Zhang. Tra2: the dominant power of alternative splicing in tumors. Heliyon, 9:e15516, Apr 2023. URL: https://doi.org/10.1016/j.heliyon.2023.e15516, doi:10.1016/j.heliyon.2023.e15516. This article has 19 citations.

9. (grellscheid2011identificationofevolutionarily pages 1-2): Sushma Grellscheid, Caroline Dalgliesh, Markus Storbeck, Andrew Best, Yilei Liu, Miriam Jakubik, Ylva Mende, Ingrid Ehrmann, Tomaz Curk, Kristina Rossbach, Cyril F. Bourgeois, James Stévenin, David Grellscheid, Michael S. Jackson, Brunhilde Wirth, and David J. Elliott. Identification of evolutionarily conserved exons as regulated targets for the splicing activator tra2β in development. PLoS Genetics, 7:e1002390, Dec 2011. URL: https://doi.org/10.1371/journal.pgen.1002390, doi:10.1371/journal.pgen.1002390. This article has 103 citations and is from a domain leading peer-reviewed journal.

10. (grellscheid2011identificationofevolutionarily pages 5-6): Sushma Grellscheid, Caroline Dalgliesh, Markus Storbeck, Andrew Best, Yilei Liu, Miriam Jakubik, Ylva Mende, Ingrid Ehrmann, Tomaz Curk, Kristina Rossbach, Cyril F. Bourgeois, James Stévenin, David Grellscheid, Michael S. Jackson, Brunhilde Wirth, and David J. Elliott. Identification of evolutionarily conserved exons as regulated targets for the splicing activator tra2β in development. PLoS Genetics, 7:e1002390, Dec 2011. URL: https://doi.org/10.1371/journal.pgen.1002390, doi:10.1371/journal.pgen.1002390. This article has 103 citations and is from a domain leading peer-reviewed journal.

11. (dalgliesh2025anultraconservedpoison pages 1-2): Caroline Dalgliesh, Saad Aldalaqan, Christian Atallah, Andrew Best, Emma Scott, Ingrid Ehrmann, George Merces, Joel Mannion, Barbora Badurova, Raveen Sandher, Ylva Illing, Brunhilde Wirth, Sara Wells, Gemma Codner, Lydia Teboul, Graham R Smith, Ann Hedley, Mary Herbert, Dirk G de Rooij, Colin Miles, Louise N Reynard, and David J Elliott. An ultra-conserved poison exon in the tra2b gene encoding a splicing activator is essential for male fertility and meiotic cell division. The EMBO Journal, 44:877-902, Jan 2025. URL: https://doi.org/10.1038/s44318-024-00344-6, doi:10.1038/s44318-024-00344-6. This article has 7 citations.

12. (dalgliesh2025ultra‐conservedpoisonexons pages 2-4): Caroline Dalgliesh, Farimah Ghorbani, Adam J. M. Wollman, and David J. Elliott. Ultra‐conserved poison exons enable rapid and safe splicing factor gene expression switches: a hypothesis. BioEssays, Nov 2025. URL: https://doi.org/10.1002/bies.70081, doi:10.1002/bies.70081. This article has 0 citations and is from a peer-reviewed journal.

13. (swarup2025dualroleof pages 7-9): Evan Swarup and Hongyu Qiu. Dual role of transformer 2 beta as both a developmental necessity and a disease modulator. International Journal of Molecular Sciences, 26:8805, Sep 2025. URL: https://doi.org/10.3390/ijms26188805, doi:10.3390/ijms26188805. This article has 0 citations.

14. (swarup2025dualroleof pages 14-15): Evan Swarup and Hongyu Qiu. Dual role of transformer 2 beta as both a developmental necessity and a disease modulator. International Journal of Molecular Sciences, 26:8805, Sep 2025. URL: https://doi.org/10.3390/ijms26188805, doi:10.3390/ijms26188805. This article has 0 citations.

15. (pihlajamaki2011expressionofthe pages 1-2): Jussi Pihlajamäki, Carles Lerin, Paula Itkonen, Tanner Boes, Thomas Floss, Joshua Schroeder, Farrell Dearie, Sarah Crunkhorn, Furkan Burak, Josep C. Jimenez-Chillaron, Tiina Kuulasmaa, Pekka Miettinen, Peter J. Park, Imad Nasser, Zhenwen Zhao, Zhaiyi Zhang, Yan Xu, Wolfgang Wurst, Hongmei Ren, Andrew J. Morris, Stefan Stamm, Allison B. Goldfine, Markku Laakso, and Mary Elizabeth Patti. Expression of the splicing factor gene sfrs10 is reduced in human obesity and contributes to enhanced lipogenesis. Cell metabolism, 14 2:208-18, Aug 2011. URL: https://doi.org/10.1016/j.cmet.2011.06.007, doi:10.1016/j.cmet.2011.06.007. This article has 189 citations and is from a highest quality peer-reviewed journal.

16. (pihlajamaki2011expressionofthe pages 4-5): Jussi Pihlajamäki, Carles Lerin, Paula Itkonen, Tanner Boes, Thomas Floss, Joshua Schroeder, Farrell Dearie, Sarah Crunkhorn, Furkan Burak, Josep C. Jimenez-Chillaron, Tiina Kuulasmaa, Pekka Miettinen, Peter J. Park, Imad Nasser, Zhenwen Zhao, Zhaiyi Zhang, Yan Xu, Wolfgang Wurst, Hongmei Ren, Andrew J. Morris, Stefan Stamm, Allison B. Goldfine, Markku Laakso, and Mary Elizabeth Patti. Expression of the splicing factor gene sfrs10 is reduced in human obesity and contributes to enhanced lipogenesis. Cell metabolism, 14 2:208-18, Aug 2011. URL: https://doi.org/10.1016/j.cmet.2011.06.007, doi:10.1016/j.cmet.2011.06.007. This article has 189 citations and is from a highest quality peer-reviewed journal.

17. (pihlajamaki2011expressionofthe pages 3-4): Jussi Pihlajamäki, Carles Lerin, Paula Itkonen, Tanner Boes, Thomas Floss, Joshua Schroeder, Farrell Dearie, Sarah Crunkhorn, Furkan Burak, Josep C. Jimenez-Chillaron, Tiina Kuulasmaa, Pekka Miettinen, Peter J. Park, Imad Nasser, Zhenwen Zhao, Zhaiyi Zhang, Yan Xu, Wolfgang Wurst, Hongmei Ren, Andrew J. Morris, Stefan Stamm, Allison B. Goldfine, Markku Laakso, and Mary Elizabeth Patti. Expression of the splicing factor gene sfrs10 is reduced in human obesity and contributes to enhanced lipogenesis. Cell metabolism, 14 2:208-18, Aug 2011. URL: https://doi.org/10.1016/j.cmet.2011.06.007, doi:10.1016/j.cmet.2011.06.007. This article has 189 citations and is from a highest quality peer-reviewed journal.

18. (swarup2025dualroleof pages 12-14): Evan Swarup and Hongyu Qiu. Dual role of transformer 2 beta as both a developmental necessity and a disease modulator. International Journal of Molecular Sciences, 26:8805, Sep 2025. URL: https://doi.org/10.3390/ijms26188805, doi:10.3390/ijms26188805. This article has 0 citations.

19. (swarup2025dualroleof pages 9-10): Evan Swarup and Hongyu Qiu. Dual role of transformer 2 beta as both a developmental necessity and a disease modulator. International Journal of Molecular Sciences, 26:8805, Sep 2025. URL: https://doi.org/10.3390/ijms26188805, doi:10.3390/ijms26188805. This article has 0 citations.

20. (brittain2026splicingfactortra2b pages 9-10): Nicholas Brittain, Alec Paschalis, Ryan Nelson, Beth Adamson, Laura Walker, Ruaridh Duncan, Graham R. Smith, Suzanne McGill, Richard J.S. Burchmore, Denisa Bogdan, Juan M. Jiménez-Vacas, Jonathan Welti, Wei Yuan, Craig N. Robson, Pasquale Rescigno, Sara Luzzi, Adam Sharp, Johann de Bono, and Luke Gaughan. Splicing factor tra2b enhances synthesis of androgen receptor variant ar-v7 in prostate cancer cells. Journal of Clinical Investigation, Apr 2026. URL: https://doi.org/10.1172/jci198264, doi:10.1172/jci198264. This article has 1 citations and is from a highest quality peer-reviewed journal.

21. (brittain2026splicingfactortra2b pages 1-2): Nicholas Brittain, Alec Paschalis, Ryan Nelson, Beth Adamson, Laura Walker, Ruaridh Duncan, Graham R. Smith, Suzanne McGill, Richard J.S. Burchmore, Denisa Bogdan, Juan M. Jiménez-Vacas, Jonathan Welti, Wei Yuan, Craig N. Robson, Pasquale Rescigno, Sara Luzzi, Adam Sharp, Johann de Bono, and Luke Gaughan. Splicing factor tra2b enhances synthesis of androgen receptor variant ar-v7 in prostate cancer cells. Journal of Clinical Investigation, Apr 2026. URL: https://doi.org/10.1172/jci198264, doi:10.1172/jci198264. This article has 1 citations and is from a highest quality peer-reviewed journal.

22. (swarup2025dualroleof pages 4-6): Evan Swarup and Hongyu Qiu. Dual role of transformer 2 beta as both a developmental necessity and a disease modulator. International Journal of Molecular Sciences, 26:8805, Sep 2025. URL: https://doi.org/10.3390/ijms26188805, doi:10.3390/ijms26188805. This article has 0 citations.

23. (dalgliesh2025ultra‐conservedpoisonexons pages 6-7): Caroline Dalgliesh, Farimah Ghorbani, Adam J. M. Wollman, and David J. Elliott. Ultra‐conserved poison exons enable rapid and safe splicing factor gene expression switches: a hypothesis. BioEssays, Nov 2025. URL: https://doi.org/10.1002/bies.70081, doi:10.1002/bies.70081. This article has 0 citations and is from a peer-reviewed journal.

24. (xue2023tra2thedominant pages 7-8): Jiancheng Xue, Tie Ma, and Xiaowen Zhang. Tra2: the dominant power of alternative splicing in tumors. Heliyon, 9:e15516, Apr 2023. URL: https://doi.org/10.1016/j.heliyon.2023.e15516, doi:10.1016/j.heliyon.2023.e15516. This article has 19 citations.

Artifacts

• Edison artifact artifact-00
• Edison artifact artifact-01

Citations

1. swarup2025dualroleof pages 1-2
2. swarup2025dualroleof pages 2-4
3. grellscheid2011identificationofevolutionarily pages 4-5
4. grellscheid2011identificationofevolutionarily pages 5-6
5. grellscheid2011identificationofevolutionarily pages 1-2
6. swarup2025dualroleof pages 7-9
7. swarup2025dualroleof pages 4-6
8. pihlajamaki2011expressionofthe pages 1-2
9. pihlajamaki2011expressionofthe pages 4-5
10. dalgliesh2025anultraconservedpoison pages 1-2
11. swarup2025dualroleof pages 9-10
12. swarup2025dualroleof pages 12-14
13. swarup2025dualroleof pages 14-15
14. pihlajamaki2011expressionofthe pages 3-4
15. https://doi.org/10.3390/ijms26188805,
16. https://doi.org/10.1038/ncomms5760,
17. https://doi.org/10.1016/j.heliyon.2023.e15516,
18. https://doi.org/10.1371/journal.pgen.1002390,
19. https://doi.org/10.1038/s44318-024-00344-6,
20. https://doi.org/10.1002/bies.70081,
21. https://doi.org/10.1016/j.cmet.2011.06.007,
22. https://doi.org/10.1172/jci198264,